Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) announced today that it is the first national laboratory to
offer customers a 21-marker genetic analysis in combination with a
double-blind process for parentage/relationship testing on every sample.
The testing utilizes two kits developed for LabCorp by Promega
Corporation of Madison, Wisconsin. The kits consist of 20 autosomal
genetic markers and one gender marker. The kits have overlapping genetic
systems that, when coupled with independent DNA extractions, yield a
double blind test for every sample.
“This new test is another example of our commitment to lead
the industry with innovative testing technology.”
The main purpose of parentage/relationship testing is to detect if the
proposed relationship is incorrect. This newest innovation greatly
increases the ability to make this determination. For paternity testing,
the number of genetic markers (known as “loci”) used by laboratories to
exclude a man in a typical case has increased over the years, giving a
more definitive result of non-paternity. With the new test panel of 21
markers, over half of the non-excluded men have combined paternity
indices of greater than one billion to one and more than 95% had
combined paternity indices greater than one million to one. When a man
is not excluded, the typical paternity test will have a probability of
paternity of 99.9999%.
“Parentage/relationship tests play an important role in child support,
probate and immigration decisions. By utilizing these new test kits,
LabCorp is providing a dramatic increase in the power to exclude,
resulting in more robust results than those routinely found in the
industry. For men who are not excluded, we have already seen combined
paternity indices in multiple cases indicating a quadrillion to one
likelihood of paternity,” said Dr. Mark Brecher, Chief Medical Officer
of LabCorp. “This new test is another example of our commitment to lead
the industry with innovative testing technology.”